(
out of
546
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Research North
Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City
,
UT
84112
Board Certification
|
American Board of Internal Medicine (Sub: Hematology)
|
Patient Rating
Patients describe Dr. McClune as caring, compassionate, and personable, frequently noting that he listens and makes them feel reassured. Reviewers emphasize his thoroughness, clear explanations, patience, and habit of taking time to answer questions and involve patients in treatment decisions. Many also praise his clinical expertise and professionalism, saying his informed, supportive approach eases them through cancer care.
Generated via Patient Reviews
5.0
/5
( out of
546 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor (Clinical) |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Sub: Hematology)
|
Education history
| Fellowship | Hematology/Oncology - University of Tennessee Health Science Center | Chief Fellow |
|---|---|---|
| Fellowship | Hematology/Oncology - University of Tennessee Health Science Center | Fellow |
| Residency | Internal Medicine - Johns Hopkins University School of Medicine | Resident |
| Professional Dental | Osteopathic Medicine - Kansas City University of Medicine and Biosciences, College of Osteopathic Medicine | D.O. |
| Undergraduate | Biochemistry - Wichita State University | B.A. |
Selected Publications
Journal Article
- Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, ODonnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS (2025). A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. Blood, 147(17), 1914-1927.
- Koehne G, Mushtaq MU, Muffly LS, Menes M, Azzi J, Bernard L, Cooper B, Kennedy V, Koura D, Maakaron J, Magenau J, McClune B, Patel SS, Rimando JC, Shah NN, Suh HC, Tamari R, Thosar S, Canesin G, Hyzy SL, Lee-Sundlov MM, Stanizzi DA, Hummel D, Lin MI, Raffel GD, Whangbo JS, DiPersio JF (2025). Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). JCO Precis Oncol, 9, e2500556.
- Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin GR (2025). The Past, Present and Future of Myeloma Staging and Risk Prognostication. Oncologist, 30(10).
- Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, DSouza A, Szabo A, Mohyuddin GR (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291.
- Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark W, Rapoport AP, Rodriguez TE, Winters JN, Davis M, Miao HM, Ray M, Fang X, Kim JJ, Oluwole OO (2025). Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis. Am J Cancer Res, 15(8), 3417-3433.
- Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ERS (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO Oncol Pract, OP2500322.
- Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma, 65(9), 1-4.
- Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 64(7), 1-4.
- Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol, 200(5), 587-594.
- McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565.
- Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48.
- Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719.
- Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4(1-2), 56-59.
- Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167, 152-160.
- Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 12(4), 74.
- Steinbach M, Julian K, McClune B, Sborov D (2022). Toxicity management Strategies for Next Generation Novel Therapeutics in Multiple Myeloma. Ther Adv Hematol, In Press.
- Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 2(4): 74.
- Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167:152-160.
- Barth D, Singleton M, Monohan G, McClune B, Adams V (2022). Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant, 31:9636897221080385.
- Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2022). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. . Eur J Cancer (1965), 56:164-174.
- Barth D, Singleton M, Monohan G, McClune B, Adams V (2022). Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant, 31, 9636897221080385.
- Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer, 156, 164-174.
- Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah AO (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(7), 489-496.
- Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21(1), 730.
- Bossart A, McClune B, Barrell K, Warner J, Majersik JJ (2021). Pearls & Oy-sters: POEMS Syndrome: An Eloquent Acronym for a Rare Disease You Don't Want to Miss. Neurology, 97(17), 835-838.
- Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395.
- Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am J Hematol, 96(6), 690-697.
- Mohyuddin GR, Abdallah AO, McClune B (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA Oncol, 7(4), 635.
- Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2020). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol, 8(4), e299-e304.
- Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 21(1), 339.
- Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK (2020). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 5(4), 1097-1101.
- Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577.
- Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune B (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematol, 7(10), e704-e706.
- Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402.
- Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency. J Cancer Educ.
- Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426.
- Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM (2018). Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv, 3(6), 875-883.
- Santiago V, Lazaryan A, McClune B, McKenna RW, Courville EL (2017). Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma, 59(4), 958-966.
- He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, Ustun C, McClune B, Arora M, Rashidi A, Eckfeldt C, Weisdorf DJ, Bejanyan N (2017). Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Transplant, 23(9), 1485-1490.
- Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M (2017). Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol, 92(9), E529-E533.
- Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL (2017). Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 4(9), e431-e442.
- Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V (2017). Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant, 52(5), 697-703.
- Fair C, Shanley R, Rogosheske J, Lazaryan A, McClune B, Brunstein CG, Bachanova V (2017). BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. Bone Marrow Transplant, 52(3), 491-493.
- Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA (2015). Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res, 21(6), 1267-72.
- Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation (2014). Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 20(8), 1183-9.
- McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ (2014). Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant, 20(7), 960-8.
- McClune BL, Majhail NS (2013). Osteoporosis after stem cell transplantation. Curr Osteoporos Rep, 11(4), 305-10.
- Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ (2013). Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant, 48(11), 1444-9.
- McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 366(19), 1770-1781.
- McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 366(19), 1770-81.
- Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ (2011). Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant, 47(4), 494-8.
- McClune B, Majhail NS, Flowers ME (2012). Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol, 49(1), 59-65.
- Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ (2010). Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant, 17(7), 1025-32.
- McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, Majhail NS (2010). Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant, 46(1), 1-9.
- McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S (2010). Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol, 28(11), 1878-87.
- McClune BL, Weisdorf DJ (2010). Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol, 17(2), 133-8.
- Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE (2008). Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant, 15(2), 214-22.
- Przepiorka D, Buadi FK, McClune B (2007). Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy, 28(1), 58-63.
- Przepiorka D, Buadi F, McClune B, Franz G, Walsh W, White F (2007). Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant, 40(8), 759-64.
Review
- Odstrcil Bobillo MS, McClune B, Couriel DR (2025). Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US. [Review]. Leuk Lymphoma, 1-11.
- Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22.
- Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13, 20406207221100659.
- Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13.
Book Chapter
- McClune BL (2015). Plasma cell neoplasms, a therapeutic approach. In McClune BL (Ed.), Plasma Cell Neoplasms: A Morphologic, Cytogenetic and Immunophenotypic Approach (pp. 123-141).
- McClune BL (2014). Clinical Considerations in Myeloma Care. In Plasma Cell Neoplasms. Springer.
- McClune BL (2014). Blood versus Marrow Allogeneic Stem Cell Transplantation. In Lazarus HM, Laughlin, MJ (Eds.), Allogeneic Stem Cell Transplantation: Clinical Research Practice (2nd Edition, pp. 281-97). Humana Press.
Letter
- Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [Letter to the editor]. Clin Hematol Int, 4(1-2), 56-59.
- Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2020). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621.
- Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2020). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760.
- Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762.
- Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522.
- Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256.
- McClune BL, Defor T, Brunstein C, Vogel RI, Majhail NS, Bachanova V, Burns LJ, Slungaard A, Weisdorf DJ (2011). Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. [Letter to the editor]. Br J Haematol, 156(2), 273-5.
- McClune B, Buadi FK, Aslam N, Przepiorka D (2007). Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. [Letter to the editor]. Leuk Lymphoma, 48(9), 1849-51.
Abstract
- Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM, Efebera YA, Ganguly SGasparetto C, Geller N, Giralt SAHari PH, Horowitz MH, Koreth JLandau H, McCarthy P, McClune B, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Somlo G, Krishnan A (2016). Comparison of Autologous Hematopoietic Cell Transplant (auto HCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Auto Hct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) [Abstract]. 128, LBA1.
- Shune L, Weisdorf DJ, McClune B, et al (2009). Allogeneic hematopoietic cell transplant for multiple myeloma: Comparative results of planned therapy versus salvage therapy [Abstract]. 27(15s), suppl; abstract 7035.
- McClune B, Burns L, Defor T, Slungaard A, Bachanova V, Brunstein B, Weisdorf D (2009). Hematopoietic cell transplantation for chronic lymphocytic leukemia: similar efficacy of non- myeloablative and myeloablative conditioning; long-term evaluation from the University of Minnesota [Abstract]. 114, abstract 3385.
- Waheed S, McClune B, Buadi F, Wright K, Przepiorka D (2006 (June 20 Supplement)). The effect of changes in the treatment paradigm for chronic lymphocytic leukemia: A tumor registry study [Abstract]. 24(18S), 16000.
- Crenshaw C, Brenner S, McClune B, Bradley R, Przepiorka D (2006). In vivo validation of single platform measurement of CD34 in peripheral blood stem cells [Abstract]. 8, 54.
- Buadi F, McClune B, Hull Y, Yunus F, Minhas S, Przepiorka D (2005). The addition of rituximab to standard high dose BEAM chemotherapy for autologous stem cell transplant in patients with lymphoma does have a significant effect on engraftment [Abstract]. 106, 5325.
- McClune B, Buadi F, Hull Y, Yunus F, Minhas S, Walsh W, Przepiorka D (2005). The natural history of relapse after transplantation for myeloma [Abstract]. 106, 5511.
- McClune B, Kumar B, Buadi F, Womeodu R, Wright K, Baskin R, Minhas S, Ratliff TW, Spiers K, Yunus F, Przepiorka D (2004). African Americans and Caucasians with myeloma have similar outcomes in the current era: A tumor registry study [Abstract]. 104, abstract 857.
- Buadi F, McClune B, Moore Y, Womeodu R, Yunus F, Walsh W, Minhas S, Przepiorka D (2004). Race has no effect on survival in multiple myeloma patients undergoing autologous stem cell transplantation [poster presentation also given at American Society of Hematology Annual Meeting, San Diego CA] [Abstract]. 104, abstract 357.
I completely trusted Dr. McClune not only was he an outstanding doctor to me I know he genuinely cared about my health and was my friend!!!
Very caring doctor. Explains everything in language I could understand. He took his time with me.
Very kind, compassionate doctor, He also knows his job very well, one of best, and intelligent , Thank you
The doctor is very thorough and treat you with great respect and listens to your explanations of how your body is feeling and then gives you good help
Dr. McClune is without a doubt extremely knowledgeable and competent in his profession. However, to me his greatest attribute is the way he treats his patients. He is patient, he listens to what I have to say, and he truly cares about my overall health, not just the cancer they are dealing with. He is one of the finest doctor's I have ever had the pleasure of working with.
He is not only exceptionally skilled in his specialty, he is also very caring.
He is a very caring professional!
Thank you for being kind, compassionate, thorough and straightforward. Thank you forctaking the time to discuss mt Healthcare at great length and in understandable language. And thank you for answering all of mt questions.
He is a very patient and excellent oncologist. The translator and all the staff were very kind. Thank you for your service. [TRANSLATED]
Dr. McClune goes over all test results so I understand what is happening. We discuss options and he involves me in my treatment plan.
Dr. McClune is caring and works tirelessly to provide my best care. He explains everything so I understand my plan of care!
Dr. McClune's care and expertise are absolutely top notch.
Dr. McClune has educated me on my specific condition and the current options available to treat them. I feel informed regarding my treatment and treatment goals as a result. I also feel that he truly cares about my case and my care.
He's an excellent doctor, very experienced and very kind. He tries to identify the problem. He's very professional. [TRANSLATED]
Good careing doctor
Dr. McClune is great! Listens well and has good responses to questions. And has great socks!!
Dr McClune is a very incredible human and doctor. I never feel like he's in a hurry to get to the next patient. He makes me feel like I am the most important part of his day. I like the way he explains everything so I completely understand the issue. I will always recommend him to anyone looking for a multiple myeloma specialist.
Very informative and patient when discussing options and procedures. Took plenty of time with explaining procedures pros and cons.
Kind and competent, Dr. McClune provides shared decision-making in healthcare choices. I trust him and know he is my advocate.
Dr. Mcclune treats me like my case is the of the upmost importance. He analyzes every test result and makes sure that all concerns are addressed. He personally called and referred me to a secondary specialist to run needed tests. When all test results are in, he will schedule a follow up to discuss the results.
Dr. Mcclune is caring and thorough about all aspects of my disease and recovery process. He is a wonderful provider!
Very good doctor
Absolutely the best doctor for multiple myeloma.
Dr. McClune is wonderful and truly cares about patients and their wellbeing. I'm so thankful for him as my oncologist.
Dr. Mcclune is very through, made sure I understood the things he was talking about even though they were things that were hard to understand. Made sure tests he ordered were done soon. He seems to really care about his patients.
Dr McClune is my favorite doctor. He's thorough, kind and answers all my questions.
Great doctor, very professional and truly cares about his patients.
Dr. McClune is caring and personable. He listens to my concerns and involves me in my treatment plan. Wonderful provider!!
Dr. McClune and the BMT staff are some of the most competent and caring medical professionals I have ever had the pleasure of working with. Coming to HCI for my cancer treatment had been one of the best choices I have ever made. Thank you for 17 years of your loving care.
Dr. McClune listens to my concerns and answers my questions. He is wonderful about reviewing my progress and what my care plan involves going forward. Caring and compassionate!
Dr. McClune has shown kindness, professionalism and genuine compassion. He has treated me with a level of care as if I were his own family. Thru my entire experience at Huntsman, Dr. McClune has encouraged me and treated me with heartfelt kindness and respect, while keeping me informed in a way I can understand.
Knowledgeable, caring. Honestly made cancer less frightening.
Kind,caring!!! Never makes you feel rushed, regardless of how many question's you have. I absolutely love him & have total faith in him to get me thru this cancer/stem cell transplant journey
Dr. McClune, is not only an amazing doctor but a wonderful person. He is so caring and easy to talk to. Makes you feel assured, truly cares for his patients.
Dr. McClune is thorough and caring.
Kind, professional and very direct and respectful!
Dr McClune is a caring and very thorough physician. I'm so glad I have him as my doctor.
We appreciate Dr McClune. Very thorough.
Dr. McClune listened to my concerns and answered my questions. He is thorough with planning.